Literature DB >> 2825934

A 6-hour human parathyroid hormone (1-34) infusion protocol: studies in normal and hypoparathyroid subjects.

A McElduff1, D Lissner, M Wilkinson, C Cornish, S Posen.   

Abstract

Parathyroid hormone (PTH)-resistant states are usually diagnosed by the failure of an acute PTH injection to elicit a rise in urinary cAMP and phosphate or, less commonly, by the failure of repeated PTH injections to raise serum calcium. We have established a 6 hour infusion of human PTH (1-34) which identifies PTH-resistant hypoparathyroid subjects on the basis of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and calcium responses. 1,25-Dihydroxyvitamin D levels increased by at least 58 pmol/liter and serum calcium by at least 0.1 mmol/liter in PTH-responsive hypoparathyroid subjects (n = 6), whereas in pseudohypoparathyroid subjects (n = 5) these levels rose by less than 22 pmol/liter and 0.06 mmol/liter respectively. The responsiveness of urinary phosphate excretion, expressed as the renal threshold phosphate concentration (TmPO4/GFR), to PTH also clearly separated the pseudohypoparathyroid patients from the other subjects. Differences in urinary calcium responses were observed though this parameter was less reliable in the identification of individual PTH-resistant or PTH-sensitive hypoparathyroid patients. Nephrogenous cAMP did not discriminate between groups when this protocol was used. This test has the potential to facilitate and extend the classification of PTH-resistant states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825934     DOI: 10.1007/BF02555228

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

1.  Evidence for a defect in the formation of 1alpha,25-dihydroxyvitamin D in pseudohypoparathyroidism.

Authors:  T K Sinha; H F DeLuca; N H Bell
Journal:  Metabolism       Date:  1977-07       Impact factor: 8.694

2.  Further studies on pseudo-hypoparathyroidism: report of four new cases.

Authors:  H ELRICK; F ALBRIGHT; F C BARTTER; A P FORBES; J D REEVES
Journal:  Acta Endocrinol (Copenh)       Date:  1950

3.  Effects of nucleotides, hormones, ions, and 1,25-dihydroxycholecalciferon on 1,25-dihydroxycholecalciferol production in isolated chick renal tubules.

Authors:  R G Larkins; S J MacAuley; A Rapoport; T J Martin; B R Tulloch; P G Byfield; E W Matthews; I MacIntyre
Journal:  Clin Sci Mol Med       Date:  1974-05

4.  Renal handling of phosphate.

Authors:  C L Mizgala; G A Quamme
Journal:  Physiol Rev       Date:  1985-04       Impact factor: 37.312

5.  Clinical experiences with human parathyroid hormone 1-34.

Authors:  T J Furlong; M S Seshadri; M R Wilkinson; C J Cornish; B Luttrell; S Posen
Journal:  Aust N Z J Med       Date:  1986-12

6.  Renal 1,25-dihydroxyvitamin D, phosphaturic, and cyclic-AMP responses to intravenous synthetic human parathyroid hormone-(1-34) administration in normal subjects.

Authors:  D M Slovik; M A Daly; J T Potts; R M Neer
Journal:  Clin Endocrinol (Oxf)       Date:  1984-04       Impact factor: 3.478

7.  Effect of parathyroid hormone on 1,25-dihydroxyvitamin D formation in type I pseudohypoparathyroidism.

Authors:  L Aksnes; D Aarskog
Journal:  J Clin Endocrinol Metab       Date:  1980-12       Impact factor: 5.958

8.  A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies.

Authors:  T A Reinhardt; R L Horst; J W Orf; B W Hollis
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

9.  Defect of receptor-cyclase coupling protein in psudohypoparathyroidism.

Authors:  Z Farfel; A S Brickman; H R Kaslow; V M Brothers; H R Bourne
Journal:  N Engl J Med       Date:  1980-07-31       Impact factor: 91.245

10.  Effect of dibutyryl adenosine 3',5'-monophosphate administration on plasma concentrations of 1,25-dihydroxyvitamin D in pseudohypoparathyroidism type I.

Authors:  K Yamaoka; Y Seino; M Ishida; T Ishii; T Shimotsuji; Y Tanaka; H Kurose; S Matsuda; K Satomura; H Yabuuchi
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

View more
  2 in total

1.  (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Authors:  Orlando M Gutiérrez; Kelsey T Smith; Allison Barchi-Chung; Neha M Patel; Tamara Isakova; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2012-01       Impact factor: 8.237

2.  Antiidiotypic PTH antibodies as a cause of elevated immunoreactive parathyroid hormone in idiopathic hypoparathyroidism, a second case: another manifestation of autoimmune endocrine disease?

Authors:  A McElduff; M Lackmann; M Wilkinson
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.